Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant

  title={Development and Characterization of Synthetic Glucopyranosyl Lipid Adjuvant System as a Vaccine Adjuvant},
  author={R. Coler and S. Bertholet and M. Moutaftsi and Jeff Guderian and H. Windish and S. Baldwin and Elsa M. Laughlin and M. S. Duthie and Christopher B Fox and D. Carter and M. Friede and T. Vedvick and S. Reed},
  journal={PLoS ONE},
  • R. Coler, S. Bertholet, +10 authors S. Reed
  • Published 2011
  • Biology, Medicine
  • PLoS ONE
  • Innate immune responses to vaccine adjuvants based on lipopolysaccharide (LPS), a component of Gram-negative bacterial cell walls, are driven by Toll-like receptor (TLR) 4 and adaptor proteins including MyD88 and TRIF, leading to the production of inflammatory cytokines, type I interferons, and chemokines. We report here on the characterization of a synthetic hexaacylated lipid A derivative, denoted as glucopyranosyl lipid adjuvant (GLA). We assessed the effects of GLA on murine and human… CONTINUE READING
    240 Citations

    Paper Mentions

    Interventional Clinical Trial
    The clinical trial phase 2b is designed to assess the safety and the specific immune response of the active ingredient (protein + adjuvant) in healthy and then in infected school… Expand
    InterventionBiological, Drug
    Interventional Clinical Trial
    The clinical trial phase 2a is designed to assess the safety of the active ingredient (protein + adjuvant) and secondarily its immunogenicity in healthy male adults from 18 to 49… Expand
    InterventionBiological, Drug
    Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A
    • 37
    • PDF
    The stimulatory effect of the TLR4-mediated adjuvant glucopyranosyl lipid A is well preserved in old age
    • 12
    Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery
    • 37
    • PDF
    The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction
    • 26
    • PDF


    The Vaccine Adjuvant Monophosphoryl Lipid A as a TRIF-Biased Agonist of TLR4
    • 696
    Enhancement of antigen-specific immunity via the TLR4 ligands MPL™ adjuvant and Ribi.529
    • 227
    Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations.
    • 98
    Selective Activation of the p38 MAPK Pathway by Synthetic Monophosphoryl Lipid A*
    • 79
    • Highly Influential
    • PDF
    Bacterial lipopolysaccharides and innate immunity.
    • 561
    Synthetic and natural TLR4 agonists as safe and effective vaccine adjuvants.
    • 55
    Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells
    • 867
    • PDF
    Structural Regions of MD-2 That Determine the Agonist-Antagonist Activity of Lipid IVa*
    • 63
    • PDF
    Adjuvants--a balance between toxicity and adjuvanticity.
    • 540